JP6400580B2 - ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法 - Google Patents

３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法 Download PDF

Info

Publication number
JP6400580B2
JP6400580B2 JP2015526838A JP2015526838A JP6400580B2 JP 6400580 B2 JP6400580 B2 JP 6400580B2 JP 2015526838 A JP2015526838 A JP 2015526838A JP 2015526838 A JP2015526838 A JP 2015526838A JP 6400580 B2 JP6400580 B2 JP 6400580B2
Authority
JP
Japan
Prior art keywords
compound
coch
cinnamyl
formylrifamycin
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015526838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528823A (ja
Inventor
キリル・アセノフ・ニノフ
ヴェリチカ・イリエヴァ・アポストロヴァ−ディモヴァ
エフティミア・イヴァノーヴァ・ステファノヴァ
ロッセン・クルモフ・コイチェフ
コンスタンチノヴァ，ルミャーナ・ゲオルギエヴァ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015528823A publication Critical patent/JP2015528823A/ja
Application granted granted Critical
Publication of JP6400580B2 publication Critical patent/JP6400580B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
JP2015526838A 2012-08-13 2013-08-09 ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法 Expired - Fee Related JP6400580B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BG111288 2012-08-13
BG11128812 2012-08-13
PCT/BG2013/000041 WO2014026254A1 (en) 2012-08-13 2013-08-09 Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018165179A Division JP6694029B2 (ja) 2012-08-13 2018-09-04 ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法

Publications (2)

Publication Number Publication Date
JP2015528823A JP2015528823A (ja) 2015-10-01
JP6400580B2 true JP6400580B2 (ja) 2018-10-03

Family

ID=50101135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015526838A Expired - Fee Related JP6400580B2 (ja) 2012-08-13 2013-08-09 ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法
JP2018165179A Active JP6694029B2 (ja) 2012-08-13 2018-09-04 ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018165179A Active JP6694029B2 (ja) 2012-08-13 2018-09-04 ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法

Country Status (18)

Country Link
US (2) US9682997B2 (en:Method)
EP (1) EP2882435B8 (en:Method)
JP (2) JP6400580B2 (en:Method)
KR (1) KR102210848B1 (en:Method)
CN (2) CN107840854A (en:Method)
BR (1) BR112015002945B1 (en:Method)
CA (1) CA2881958C (en:Method)
EA (1) EA029363B1 (en:Method)
ES (1) ES2876004T3 (en:Method)
HK (1) HK1248691A1 (en:Method)
HU (1) HUE054955T2 (en:Method)
IN (1) IN2015DN02009A (en:Method)
MX (1) MX380259B (en:Method)
PL (1) PL2882435T3 (en:Method)
PT (1) PT2882435T (en:Method)
UA (1) UA120030C2 (en:Method)
WO (1) WO2014026254A1 (en:Method)
ZA (1) ZA201501268B (en:Method)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020102511A (ru) 2017-06-26 2021-07-27 Биофер С.П.А. Соединения пиридо-имидазо рифамицина в качестве антибактериального средства
TWI731295B (zh) * 2019-01-24 2021-06-21 宏碁股份有限公司 顯示裝置以及控制顯示裝置的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478563A (en) 1975-03-05 1977-07-06 Lepetit Spa Rifamycin derivatives
GR64108B (en) 1977-04-15 1980-01-24 Dso Pharmachim Method for the preparation of azomethine-derivatives of rifamycin s.v
US4179439A (en) * 1977-07-01 1979-12-18 Intreprinderea De Antibiotice Iasi Rifamycins and method for their preparation
US4193020A (en) 1978-05-22 1980-03-11 Sperry Rand Corporation Phase lock control system with trajectory correction
JPS5738742A (en) * 1980-08-21 1982-03-03 Kawasaki Kasei Chem Ltd Preparation of 1,4-dihydroanthraquinone
JPS5695190A (en) * 1980-09-17 1981-08-01 Intorepurinderea De Anteibiote Manufacture of rifamycin derivative
IT1201963B (it) * 1983-03-24 1989-02-02 Prodotti Antibiotici Spa Derivati delle rifamicine e procedimento per la loro preparazione
JPS6143132A (ja) * 1984-08-06 1986-03-01 Takeda Chem Ind Ltd キノン誘導体，その製造法およびそれを含んでなる医薬組成物
JPS63501712A (ja) * 1985-10-18 1988-07-14 チバ−ガイギ− アクチエンゲゼルシヤフト 置換４−ベンジルピペラジニル化合物
IT1202424B (it) * 1987-01-26 1989-02-09 Prodotti Antibiotici Spa Sali di un derivato rifamicinico
EP0284552A1 (de) * 1987-03-06 1988-09-28 Ciba-Geigy Ag 4-Benzyl-piperazinyl-Hydrazone
BG48618A1 (en) 1988-02-23 1991-04-15 Nauchen Inst Promishlena Mikro Method for preparing riphampycin
JPH02215716A (ja) * 1989-02-08 1990-08-28 Farmitalia Carlo Erba Spa ３―（ｎ―ピペリジノメチル―アジノ）メチルリファマイシンｓを活性成分として含有する薬剤組成物
US5095108A (en) 1990-08-28 1992-03-10 Technologichen Kombinat Za Promishlena Microbiologia Non-solvated crystalline form "A" of 3-(4-cynnamyl-1-piperazinyl)iminomethylrifamycine SV and a method of its production
BG64021B1 (bg) * 1998-11-04 2003-10-31 КОНСТАНТИНОВА Румяна Натриева сол на 3-(4-цинамил-1-пиперазинил)-иминометил рифамицин и метод за получаването й
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
DE10038101A1 (de) * 2000-08-04 2002-02-14 Degussa Verfahren zur Herstellung von 2-(4-Methyl-3-pentenyl)-anthrachinon
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US7226931B2 (en) * 2004-07-22 2007-06-05 Cumbre Pharmaceuticals Inc. (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations

Also Published As

Publication number Publication date
US9981985B2 (en) 2018-05-29
HUE054955T2 (hu) 2021-10-28
ZA201501268B (en) 2016-01-27
EA029363B1 (ru) 2018-03-30
CA2881958A1 (en) 2014-02-20
KR20150042275A (ko) 2015-04-20
CA2881958C (en) 2019-08-27
BR112015002945A8 (pt) 2018-01-16
EP2882435A4 (en) 2017-05-03
EP2882435B1 (en) 2021-03-17
EP2882435A1 (en) 2015-06-17
KR102210848B1 (ko) 2021-02-02
BR112015002945B1 (pt) 2021-08-31
ES2876004T3 (es) 2021-11-11
US20150368263A1 (en) 2015-12-24
PT2882435T (pt) 2021-06-18
JP6694029B2 (ja) 2020-05-13
JP2015528823A (ja) 2015-10-01
IN2015DN02009A (en:Method) 2015-08-14
BR112015002945A2 (pt) 2017-12-05
EP2882435B8 (en) 2024-01-03
PL2882435T3 (pl) 2021-10-04
HK1206980A1 (en) 2016-01-22
UA120030C2 (uk) 2019-09-25
MX380259B (es) 2025-03-12
CN104736152B (zh) 2018-01-23
CN104736152A (zh) 2015-06-24
US20170283433A1 (en) 2017-10-05
WO2014026254A1 (en) 2014-02-20
CN107840854A (zh) 2018-03-27
MX2015001963A (es) 2015-06-04
JP2018199718A (ja) 2018-12-20
HK1248691A1 (zh) 2018-10-19
US9682997B2 (en) 2017-06-20
EA201590278A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
CN1243541C (zh) 2－(α－羟基戊基)苯甲酸盐及其制法和用途
AU2014336747B2 (en) Crystal form of (r)-praziquantel and preparation method and application thereof
EP0579681B1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
WO2018000250A1 (zh) 依鲁替尼新晶型及其制备方法
JP6694029B2 (ja) ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法
TWI530501B (zh) 純化十字孢靈素之方法
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
JP3190679B2 (ja) 複素環式化学
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
JPS6232170B2 (en:Method)
HK1206980B (en) Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation
JPH0567128B2 (en:Method)
CN118359591A (zh) 一种化合物与氨基酸的固体形式及其制备方法和用途
CN101450914B (zh) 苯甲酸衍生物
WO2014023027A1 (zh) 盐酸埃罗替尼多晶型物及其制备方法
KR20100125124A (ko) 피타바스타틴 헤미칼슘염의 신규한 결정형 및 그의 제조방법

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180905

R150 Certificate of patent or registration of utility model

Ref document number: 6400580

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees